ATE446104T1 - Rekombinantes super-verbindungs-interferon zur verwendung als hepatitis b oberflächenatigen und e-antigen-inhibitor - Google Patents

Rekombinantes super-verbindungs-interferon zur verwendung als hepatitis b oberflächenatigen und e-antigen-inhibitor

Info

Publication number
ATE446104T1
ATE446104T1 AT02702211T AT02702211T ATE446104T1 AT E446104 T1 ATE446104 T1 AT E446104T1 AT 02702211 T AT02702211 T AT 02702211T AT 02702211 T AT02702211 T AT 02702211T AT E446104 T1 ATE446104 T1 AT E446104T1
Authority
AT
Austria
Prior art keywords
hepatitis
atagen
interferon
recombinant super
antigen inhibitor
Prior art date
Application number
AT02702211T
Other languages
English (en)
Inventor
Guangwen Wei
Rongbing Guo
Renhuai Zhang
Original Assignee
Sichuan Biotechnology Res Ct
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sichuan Biotechnology Res Ct filed Critical Sichuan Biotechnology Res Ct
Application granted granted Critical
Publication of ATE446104T1 publication Critical patent/ATE446104T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/555—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Hematology (AREA)
  • Pulmonology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AT02702211T 2001-02-28 2002-02-28 Rekombinantes super-verbindungs-interferon zur verwendung als hepatitis b oberflächenatigen und e-antigen-inhibitor ATE446104T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CNB011043679A CN1245215C (zh) 2001-02-28 2001-02-28 重组高效复合干扰素用作乙型肝炎表面抗原和e抗原抑制剂
PCT/CN2002/000128 WO2002080958A1 (fr) 2001-02-28 2002-02-28 Interferon supercompose de recombinaison utilise comme inhibiteur de l'antigene de surface et de l'antigene e de l'hepatite b

Publications (1)

Publication Number Publication Date
ATE446104T1 true ATE446104T1 (de) 2009-11-15

Family

ID=4653854

Family Applications (1)

Application Number Title Priority Date Filing Date
AT02702211T ATE446104T1 (de) 2001-02-28 2002-02-28 Rekombinantes super-verbindungs-interferon zur verwendung als hepatitis b oberflächenatigen und e-antigen-inhibitor

Country Status (10)

Country Link
US (3) US7364724B2 (de)
EP (1) EP1371373B1 (de)
JP (1) JP4617058B2 (de)
CN (1) CN1245215C (de)
AT (1) ATE446104T1 (de)
AU (1) AU2003248419B2 (de)
CA (1) CA2439503A1 (de)
DE (1) DE60234085D1 (de)
HK (1) HK1061201A1 (de)
WO (1) WO2002080958A1 (de)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050079579A1 (en) * 2001-02-28 2005-04-14 Guangwen Wei Uses of spatial configuration to modulate protein function
CN1245215C (zh) 2001-02-28 2006-03-15 四川省生物工程研究中心 重组高效复合干扰素用作乙型肝炎表面抗原和e抗原抑制剂
US8551469B2 (en) 2001-02-28 2013-10-08 Superlab Far East Limited Treatment of tumors and viral diseases with recombinant interferon alpha
US20060035327A1 (en) * 2001-02-28 2006-02-16 Guangwen Wei Recombinant super-compound interferon and uses thereof
US7335496B2 (en) * 2003-06-05 2008-02-26 Ajinomoto Co., Inc. Method for producing target substance
ES2528218T3 (es) * 2003-08-28 2015-02-05 Superlab Far East Limited Usos de interferones con estructura espacial modificada
PL2325202T3 (pl) * 2003-08-28 2015-03-31 Superlab Far East Ltd Zastosowania interferonów o zmienionej strukturze przestrzennej
US7585647B2 (en) 2003-08-28 2009-09-08 Guangwen Wei Nucleic acid encoding recombinant interferon
AU2011202683B2 (en) * 2003-08-28 2012-08-09 Superlab Far East Limited Uses of interferons with altered spatial structure
CN1740197B (zh) * 2004-08-26 2010-05-12 辉阳科技美国公司 具有全新空间构象且功效增强的重组干扰素、其制备方法及应用
CA2597317C (en) * 2005-03-09 2018-01-02 Guangwen Wei Uses of recombinant super-compound interferons
CN101525381B (zh) * 2008-03-04 2012-04-18 北京百川飞虹生物科技有限公司 一种重组复合干扰素及其表达载体的构建和表达
CN102101886A (zh) * 2009-12-18 2011-06-22 四川辉阳生命工程股份有限公司 构象改变的重组干扰素晶体、其三维结构及应用
WO2013055811A1 (en) * 2011-10-12 2013-04-18 Hitachi Chemical Co., Ltd. Ex vivo methods of predicting responsiveness of a subject to interferon therapy
CH707029B1 (de) 2011-10-21 2015-03-13 Abbvie Inc Verfahren zur Behandlung von HCV, umfassend mindestens zwei direkt wirkende antivirale Wirkstoffe, Ribavirin, aber nicht Interferon.
AU2013201532B2 (en) 2011-10-21 2014-10-02 Abbvie Ireland Unlimited Company Methods for treating HCV
US8492386B2 (en) 2011-10-21 2013-07-23 Abbvie Inc. Methods for treating HCV
US8466159B2 (en) 2011-10-21 2013-06-18 Abbvie Inc. Methods for treating HCV
TWI726291B (zh) 2013-01-07 2021-05-01 英屬維爾京群島商遠東超級實驗室有限公司 通過干擾素的經皮和/或經粘膜給藥治療骨癌、皮膚癌、皮下癌、粘膜癌和/或粘膜下癌的方法和組合物
US10677782B2 (en) 2013-11-13 2020-06-09 Superlab Far East Limited Methods of determining interferon having direct inhibitory effects on tumors and uses thereof
EP3294321A4 (de) 2015-05-12 2019-04-17 Superlab Far East Limited Verfahren zur bestimmung von interferon mit direkten hemmungsauswirkungen auf tumoren und verwendungen davon
US11192914B2 (en) 2016-04-28 2021-12-07 Emory University Alkyne containing nucleotide and nucleoside therapeutic compositions and uses related thereto

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
ZA828917B (en) 1981-12-07 1983-09-28 Hoffmann La Roche Crystalline human leukocyte interferon
US4672108A (en) 1981-12-07 1987-06-09 Hoffmann-La Roche Inc. Crystalline human leukocyte interferon
US6936694B1 (en) 1982-05-06 2005-08-30 Intermune, Inc. Manufacture and expression of large structural genes
US4462940A (en) 1982-09-23 1984-07-31 Cetus Corporation Process for the recovery of human β-interferon-like polypeptides
US4681930A (en) 1983-09-20 1987-07-21 Hoffmann-La Roche Inc. Immune interferon and a method for its extraction and purification
US5372808A (en) * 1990-10-17 1994-12-13 Amgen Inc. Methods and compositions for the treatment of diseases with consensus interferon while reducing side effect
US5441734A (en) 1993-02-25 1995-08-15 Schering Corporation Metal-interferon-alpha crystals
EP0626448A3 (de) 1993-05-26 1998-01-14 BOEHRINGER INGELHEIM INTERNATIONAL GmbH Verfahren zur Herstellung und Reinigung von alpha-Interferon
DE4329756A1 (de) 1993-09-03 1995-03-09 Boehringer Ingelheim Int Verfahren zur Herstellung und Reinigung von alpha-Interferon
US5766582A (en) 1994-10-11 1998-06-16 Schering Corporation Stable, aqueous alfa interferon solution formulations
TW426523B (en) 1995-04-06 2001-03-21 Hoffmann La Roche Interferon solution
ATE328069T1 (de) 1995-10-13 2006-06-15 Harvard College Phosphopantethenyltransferasen und deren verwendungen
US5972331A (en) 1995-12-22 1999-10-26 Schering Corporation Crystalline interferon alpha for pulmonary delivery and method for producing the same
US5874304A (en) 1996-01-18 1999-02-23 University Of Florida Research Foundation, Inc. Humanized green fluorescent protein genes and methods
US5980884A (en) 1996-02-05 1999-11-09 Amgen, Inc. Methods for retreatment of patients afflicted with Hepatitis C using consensus interferon
US6532437B1 (en) 1996-10-23 2003-03-11 Cornell Research Foundation, Inc. Crystalline frap complex
CN1186120A (zh) 1996-12-24 1998-07-01 深圳科兴生物制品有限公司 在大肠杆菌中表达作为分泌的重组人干扰素α1b蛋白
AU1619699A (en) * 1997-12-05 1999-06-28 Human Genome Sciences, Inc. Synferon, a synthetic type i interferon
US6087478A (en) 1998-01-23 2000-07-11 The Rockefeller University Crystal of the N-terminal domain of a STAT protein and methods of use thereof
KR20010024899A (ko) 1998-02-06 2001-03-26 일렉서스 피티와이 리미티드 Ｆｃ 수용체의 삼차원 구조 및 모델 및 그의 용도
CN1062565C (zh) 1998-06-29 2001-02-28 深圳九先生物工程有限公司 重组人α型复合干扰素及其制备方法和用途
KR100399156B1 (ko) 1999-11-19 2003-09-26 주식회사 엘지생명과학 α-인터페론의 용액제형
CN1175901C (zh) 1999-12-06 2004-11-17 天津华立达生物工程有限公司 一种稳定的干扰素水溶液
US20020043262A1 (en) 2000-08-22 2002-04-18 Alan Langford Spray device
US7544354B2 (en) 2000-10-27 2009-06-09 Novartis Vaccines And Diagnostics Methods of protein purification and recovery
AU2002228886B2 (en) 2000-11-03 2007-08-30 Pestka Biomedical Laboratories, Inc. Interferons, uses and compositions related thereto
CN1245215C (zh) 2001-02-28 2006-03-15 四川省生物工程研究中心 重组高效复合干扰素用作乙型肝炎表面抗原和e抗原抑制剂
US6546074B1 (en) 2001-03-27 2003-04-08 Astex Technology Limited Protein crystal structure and method for identifying protein modulators
CN1375502A (zh) 2001-10-25 2002-10-23 南京药科大学 聚乙二醇修饰重组人干扰素
US6807478B2 (en) * 2001-12-27 2004-10-19 Koninklijke Philips Electronics N.V. In-building navigation system
CN1176946C (zh) 2002-05-16 2004-11-24 中国人民解放军第二军医大学 一种新型α干扰素
CN1202861C (zh) 2003-07-18 2005-05-25 中国科学院微生物研究所 复合干扰素在治疗sars疾病中的用途
PL2325202T3 (pl) 2003-08-28 2015-03-31 Superlab Far East Ltd Zastosowania interferonów o zmienionej strukturze przestrzennej
WO2005067963A1 (en) 2003-12-23 2005-07-28 Intermune, Inc. Use of polyethylene glycol-modified interferon-alpha in therapeutic dosing regimens
CA2597317C (en) 2005-03-09 2018-01-02 Guangwen Wei Uses of recombinant super-compound interferons

Also Published As

Publication number Publication date
US20110189128A1 (en) 2011-08-04
EP1371373B1 (de) 2009-10-21
EP1371373A1 (de) 2003-12-17
US8425896B2 (en) 2013-04-23
JP4617058B2 (ja) 2011-01-19
US7364724B2 (en) 2008-04-29
CN1245215C (zh) 2006-03-15
WO2002080958A1 (fr) 2002-10-17
DE60234085D1 (de) 2009-12-03
CA2439503A1 (en) 2002-10-17
AU2003248419B2 (en) 2007-01-04
US8114395B2 (en) 2012-02-14
JP2005508848A (ja) 2005-04-07
EP1371373A4 (de) 2005-05-04
AU2003248419A1 (en) 2003-11-06
US20080305080A1 (en) 2008-12-11
US20040202641A1 (en) 2004-10-14
CN1311035A (zh) 2001-09-05
HK1061201A1 (en) 2004-09-10

Similar Documents

Publication Publication Date Title
ATE446104T1 (de) Rekombinantes super-verbindungs-interferon zur verwendung als hepatitis b oberflächenatigen und e-antigen-inhibitor
DK1476541T3 (da) Cytokin (zcytor17-ligand)
ES2523837T3 (es) Agentes de unión específica al factor de crecimiento de hepatocitos
NO20034396D0 (no) Rekombinante antistoff uttrykt sammen med GnTIII
DK1576112T3 (da) Cytokin-receptor zcytor17-multimerer
ATE263778T1 (de) Niedrigallergene proteinvarianten
DK1406656T3 (da) Fremgangsmåder til administrering af anti-TNF-alfa-antistoffer
CY1111750T1 (el) Νευροτροφικοι παραγοντες
IS7576A (is) And-mýelíntengd glýkóprótín (MAG) mótefni
HUP0402333A3 (en) Modified anti-tnf alpha antibody
ATE417275T1 (de) Puffern zur stabilizierung von hcv antigenen
CY2011020I2 (el) Νεα πεπτιδια ως αναστολεα πρωτεασης ns3-σερινης του ιου ηπατιτιδας c
HK1155720A1 (zh) 抗體對抗單核細胞趨化性蛋白
DK1294893T3 (da) Modifikation af hepatitis B-kerneantigen
LU92748I2 (fr) Virus de la diarrhée virale bovine atténué 2 (bvdv-2)
DE60207053D1 (de) Rekombinante gelatineartige proteine zur verwendung als plasmaexpander
DE60138014D1 (de) Chimäre arterivirus-ähnliche partikel
DK1501936T3 (da) Familie af cytokin-proteiner
DE50210876D1 (de) Scanmikroskop
DE60115938D1 (de) Monoklonale antikörper gegen hepatitis b virus
DE50212549D1 (de) Teilchenoptischer korrektor
ATE513564T1 (de) Immunogener rekombinanter antikörper
FR2821145B1 (fr) Brides d'echappement minces galbees
AU2002235707A1 (en) Recombination super compound interferon used as hepatitis b surface antigen and e antigen inhibitor
IT249638Y1 (it) Disposizione di proiettori di luce per l'illuminazione di dipinti.

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties